The class of compounds known as the alkylating agents had not been used extensively for in vivo antiviral drug testing until recently, when definite activity was demonstrated with a number of these chemicals in systems using certain animal leukemia viruses. For example, Cytoxan, triethylenemelamine (TEM), and Melphalan were used effectively against the Rauscher murine leukemogenic virus (Chirigos et al., 1963) . The chemical name for Cytoxan (cyclophosphamide) is 2H-1,3,2-oxazaphosphorinane, 2-[bis(2-chloroethyl)amino]-2-oxide; that of Mephalan is 2p-di-(2-chloroethyl)amino-L-phenylalanine. Cytoxan and TEM were also reportedly active against the Moloney leukemia virus (Chirigos et al., 1961) . Antiviral activity was demonstrated against the Friend leukemia virus by mitomycin C (Sugiura, 1960) and porfiromycin (Sidwell, Dixon, and Sellers, 1965) .
A recently synthesized nitrosourea, 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU), has been shown to have a primary mechanism of action related to that of the alkylating agents (Schabel et al., 1963) . Previously, BCNU was effectively used against intracerebrally or intraperitoneally (ip) inoculated leukemia L1210 (Schabel et al., 1963) and is, therefore, presumably capable of passing the blood-brain barrier. Radioisotopelabeled fragments of the drug have been recovered in the brain, as well as in other organs of the host (Wheeler, Bowdon, and Herren, 1964) . Because of this probable capability of crossing the blood-brain barrier, in addition to the demonstrated activity against L1210 mouse leukemia and Rauscher murine leukemogenic virus (Chirigos, 1964) , it was of interest to determine the activity of this compound against a broad spectrum of viruses inoculated by a variety of routes. (Bryan, Moloney, and Calnan, 1954) and was used in the form received. For use in drug evaluations, stock RSV was diluted in Eagle's (1955) bProbability that observed increase in number of survivors in the treated groups compared with the virus control group was due to chance. Determined by chi-square analysis.
c Probability that observed increase in mean survival in treated groups compared with the virus control group was due to chance. Determined by t test.
d All surviving virus-infected mice were sacrificed on day 17, and the virus titer in the blood (Bl) and brain (Br) was determined by intracerebral inoculation into 18 to 21-g indicator Swiss mice.
virus inoculation, significant increases in life span again were demonstrated among drugtreated groups. At the end of 21 days as many as 50% of the treated animals were still alive, the increases in life span varying from 2 to 11 days beyond that of the virus controls. Significant prolongation of live span was noted. The experiment was repeated with the identical treatment schedule but with slight alterations in drug doses. This second experiment ended 41 days after virus inoculation, with significant increases in life span again demonstrated, although only one virus-infected animal survived the duration of the experiment. Drug-treated animals died late in the study, indicating a delayed drug toxicity, and subsequently causing the drug control mortality to be higher than in the first experiment with this treatment schedule.
Two separate experiments were carried out with treatment schedule 3 ( (Haas and Stewart, 1956 ). Treatment of LCM virusinfected mice with other compounds, including 8-azaguanine, azaserine, 6-diazo-5-oxo-L-norleucine, 5-fluorouracil, chlorambucil, and cortisone, also increases the average life span, although to a lesser extent than MTX (Haas and Stewart, 1956; Levy and Haas, 1958; Barlow, 1962; Hotchin, 1962) . To compare the anti-LCM virus activities of BCNU and MTX, three virus concentrations (32, 100, and 1,000 LD5o) were used. The drugs were administered in a single injection ip 24 or 100 hr after virus inoculation. Four dosages of BCNU and MTX were used against the 32 LD5o virus level; a single dose of MTX was used against the 100 LD5o virus level, and three dosages were tested against the 1,000 LD5O inoculum of virus. The dosages of MTX used for the 100 hr postinoculation treatment were in the range of those described by Hotchin (1962) as being very effective when administered under the conditions used in this study. The results (Table 6 ) indicated that both compounds were effective against the LCM virus when administered 100 hr after virus inoculation. No significant antiviral activity could be demonstrated with MTX administered 24 hr after virus inoculation, whereas 40% of the BCNU-treated mice survived at the highest drug level given at this same time, and the mean survival time was lengthened at the two highest levels of BCNU. An experiment was also done to determine the comparative anti-LCM virus activities of the two compounds administered once daily for 15 days, beginning 24 hr after virus inoculation (Table 7) . Both BCNU and MTX significantly increased the mean survival time of the virusinfected mice; 10 to 50% of the mice survived the duration of the experiment when treated with slightly toxic dosages of MTX, although the same percentages of survivors occurred in the previously discussed experiments with BCNU and with similar schedules (Tables 1 and 2) .
Effect of BCNU upon infections with other viruses. A number of experiments were carried out to determine the in vivo antiviral activity of BCNU upon the other previously described viruses. The results are summarized in Tables 8  and 9 . Various treatment schedules were employed for these studies, as indicated in the tables. The doses were selected in most tests to vary from toxic to nontoxic levels. Possible antiviral activity was noted against four viruses-EEE, SF, influenza PR8, and FLV-in animals treated chronically with BCNU. In two tests with EEE virus-infected mice, a significant number survived for the duration of the experiment. In two additional experiments carried out to confirm these observations, the observed maximal increase was small, however, and the activity of BCNU against this virus was considered marginal. Increases in mean survival time of SF virus-infected mice treated with BCNU were observed, but this activity also was not seen in later tests; hence, activity against this virus may be questioned. Increases in life span of up to 2 days were observed in mice infected with the lower dose (100 LD5o) of PRS virus and treated with all nontoxic dosages of BCNU, but no activity could be demonstrated in treated mice receiving 320 LD5o of virus.
When used against FLV-infected mice, BCNU treatment resulted in a significant decrease in splenomegaly ( t Probability that the observed increase in the number of survivors in the treated groups compared with the virus control group was due to chance. Determined by chi-square analysis.
$ Probability that the observed increase in mean survival in treated groups compared to the virus control group was due to chance. Determined by t test. greater (ca. 25 %) than the spleen weight of normal Swiss mice. DISCUSSION As discussed previously, a number of agents have reportedly shown definite anti-LCM virus activity in certain in vivo systems, although, as pointed out by Levy and Haas (1958) , MTX consistently gave better protection against this virus than the other drugs tested. It is noteworthy that, in the experiments reported here, BCNU has exhibited comparable activity to MTX in similar in vivo test systems. Seldom, however, did as many treated, virus-infected animals survive as had occurred in the MTX studies reported by others (Haas and Stewart, 1956; Levy and Haas, 1958; Lerner and Haas, 1958; Hotchin, 1962) . This variation in results may have been due to a number of factors, among which may be the strain of LCM virus, the strain of mice, the dose of virus employed, timing of the drug administration, or variations in the drug lot of MTX.
Little is known of the mechanism of action of BCNU, although from available evidence two mechanisms may be speculated: first, that the activity demonstrated is a specific antiviral action and, second, that the prolongation of life in animals treated with BCNU is a result of inhibition of a "lethal" immune response to the LCM virus.
Limited evidence is available in support of the first premise, i.e., that BCNU is a true antiviral compound. Two characteristics of this compound are high lipid solubility and a low ionization constant (Schabel et al., 1963) , and it has been postulated that there is a relationship between these properties and the capacity of parenterally administered compounds to cross the blood-brain barrier and subsequently affect an intracerebrally inoculated agent (Rall and Zubrod, 1962) . The mechanisms of action of a Drugs injected ip once daily for 15 days beginning 24 hr after virus inoculation. b Probability that the observed increase in the number of survivors in the treated groups compared with the virus control group was due to chance. Determined by chi-square analysis.
c Probability that the observed increase in the mean survival in treated groups compared with the virus control group was due to chance. Determined by t test.
d Carboxymethylcellulose (0.4%) in phosphate-buffered saline.
alkylating agents, as reviewed by Wheeler (1962) and by Warwick (1963) , suggest that these agents would be capable of exerting possible antiviral action. The fact that certain other alkylating agents studied have shown antiviral activity in varying degrees would add weight to this premise. However, since surviving drugtreated mice in the present studies showed evidence of continued viral multiplication, the sparing effect rendered by treatment with BCNU may not be due to reduction or eradication of the virus. No evidence is yet available, however, to indicate whether the surviving virus observed in these studies was resistant to BCNU. A similar occurrence, in which the host was spared but the virus continued to propagate, has been reported to have taken place in a cell culture system (Furusawa, Cutting, and Furst, 1963) . It was observed that several compounds appeared to be effective, since cytopathogenic effect was prevented in Ehrlich ascites cells infected with LCM virus, but virus in high titer was continuously recovered.
The hypothesis that the observed activity of BCNU is a result of suppression of a "lethal" immune response is supported by a number of facts, all primarily based upon the observed anti-LCM virus activity exerted by other compounds. Levy and Haas (1958) speculated that the anti-LCM virus activity of MTX was due to some biochemical effect, although a possible secondary effect upon the host was also suggested. Hotchin (1962) further advanced the latter theory, indicating that a tolerance-inducing mechanism was the probable cause of the observed increased life spans. The host's immune mechanisms were thought to be depressed at a critical time during the immune response, or at least that the "learning ability" of the immune systems during the critical stages of its response to the LCM antigen was impaired. In this way an active immunity was inhibited and a tolerance to the virus resulted. The latter concepts were first stimulated and later strengthened when whole-body X irradiation (Rowe, 1956) , folic acid deficiency Stewart, 1957a, Haas, Stewart, and Briggs, 1957b) , chlorambucil (Barlow, cited by Hotchin, 1962) , and cortisone (Hotchin, 1962) , all immune response depressants, produced a mutual host-LCM virus survival. Certain of the alkylating agents (chlorambucil and myleran) apparently also can reproduce the effects of whole body X irradiation on the number of circulating platelets, lymphocytes, and neutrophils, and upon circulating antibodies (Elson, 1958; Elson, Galton, and Till, 1958; Berenbaum, 1962) .
Evidence against the latter premise of immune response suppression may be indicated in recent studies by Humphreys, Glynn, and Goldin (1963 and personal 
